Sesen Bio, Inc. (SESN): Price and Financial Metrics


Sesen Bio, Inc. (SESN): $0.50

0.02 (+4.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SESN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SESN POWR Grades

  • SESN scores best on the Value dimension, with a Value rank ahead of 75.93% of US stocks.
  • The strongest trend for SESN is in Quality, which has been heading down over the past 167 days.
  • SESN's current lowest rank is in the Growth metric (where it is better than 0.06% of US stocks).

SESN Stock Summary

  • SESN's current price/earnings ratio is 1.77, which is higher than merely 2.36% of US stocks with positive earnings.
  • Of note is the ratio of SESEN BIO INC's sales and general administrative expense to its total operating expenses; only 12.11% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for SESEN BIO INC is higher than it is for about just 0.47% of US stocks.
  • If you're looking for stocks that are quantitatively similar to SESEN BIO INC, a group of peers worth examining would be ATNX, IPA, GORO, MUX, and CDE.
  • Visit SESN's SEC page to see the company's official filings. To visit the company's web site, go to www.sesenbio.com.

SESN Valuation Summary

  • In comparison to the median Healthcare stock, SESN's price/sales ratio is 115.79% higher, now standing at 4.1.
  • Over the past 105 months, SESN's price/earnings ratio has gone up 9.

Below are key valuation metrics over time for SESN.

Stock Date P/S P/B P/E EV/EBIT
SESN 2022-09-23 4.1 0.6 1.7 0.3
SESN 2022-09-22 4.3 0.6 1.8 0.4
SESN 2022-09-21 4.5 0.6 1.9 0.5
SESN 2022-09-20 6.7 0.9 2.8 1.7
SESN 2022-09-19 6.8 1.0 2.8 1.8
SESN 2022-09-16 6.8 1.0 2.9 1.8

SESN Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 299.67%.
  • Its year over year net cashflow from operations growth rate is now at -6.86%.
  • Its 5 year cash and equivalents growth rate is now at 67.57%.
Over the past 52 weeks, SESN's revenue has gone up $2,220,000.

The table below shows SESN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 20 -28.703 47.799
2022-06-30 20 -28.703 47.799
2022-03-31 22.234 -43.249 54.317
2021-12-31 26.544 -68.878 -0.336
2021-09-30 6.544 -64.787 -24.341
2021-06-30 17.78 -54.127 -118.571

SESN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SESN has a Quality Grade of C, ranking ahead of 52.29% of graded US stocks.
  • SESN's asset turnover comes in at 0.094 -- ranking 266th of 682 Pharmaceutical Products stocks.
  • SVRA, AUPH, and ONVO are the stocks whose asset turnover ratios are most correlated with SESN.

The table below shows SESN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 511.326
2021-03-31 0.120 1 31.068
2020-12-31 0.103 1 4.319
2020-09-30 0.105 1 14.394
2020-06-30 0.000 NA 7.880
2020-03-31 0.000 NA 13.068

SESN Price Target

For more insight on analysts targets of SESN, see our SESN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.25 Average Broker Recommendation 1.67 (Moderate Buy)

SESN Stock Price Chart Interactive Chart >

Price chart for SESN

SESN Price/Volume Stats

Current price $0.50 52-week high $1.47
Prev. close $0.48 52-week low $0.37
Day low $0.47 Volume 404,900
Day high $0.52 Avg. volume 3,075,910
50-day MA $0.63 Dividend yield N/A
200-day MA $0.66 Market Cap 99.75M

Sesen Bio, Inc. (SESN) Company Bio


Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.


SESN Latest News Stream


Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream


Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.

SESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know

SESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the prior day.

Yahoo | September 29, 2022

Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Yahoo | September 21, 2022

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Yahoo | September 21, 2022

Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio

Sesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger agreement to combine the companies in an all-stock transaction. The combined company will operate under the Carisma Therapeutics moniker under the "CARM symbol" and is expected to have approximately $180 million of cash and cash equivalents, including $30 million from concurrent financing by Carisma, which is expected to fund the company through 2024. Sesen Bio suffered FDA rejection for its lead

Yahoo | September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

CAMBRIDGE, Mass. & PHILADELPHIA, September 21, 2022--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered

Yahoo | September 21, 2022

Read More 'SESN' Stories Here

SESN Price Returns

1-mo -18.80%
3-mo -45.89%
6-mo -12.22%
1-year -32.43%
3-year -57.63%
5-year -67.11%
YTD -38.65%
2021 -39.63%
2020 29.81%
2019 -26.76%
2018 75.09%
2017 -57.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6689 seconds.